Neisseria Gonorrhoeae Infection Clinical Trial
Official title:
Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study
Since the use of antibiotics, Neisseria Gonorrhoeae (NG) has acquired progressive resistance to penicillins, sulfonamides, tetracyclines and quinolones. The oropharynx is recognized as an important site for DNA exchange between NG and other commensal Neisseria, allowing NG to acquire new antimicrobial resistance. Despite the worrying data on the emergence of resistant NG, the recommendations remain to systematically treat these infections with ceftriaxone, including asymptomatic pharyngeal localizations. The objective of our study is to evaluate a ceftriaxone sparing strategy in order to limit the emergence of antibiotic resistance. The primary objective of the study is to evaluate the clearance of Neisseria gonorrhoeae, 3 months after the diagnosis of asymptomatic pharyngeal carriage documented on nucleic acid amplification test (NAAT).
Non-inferiority, multicenter, prospective, randomized open-label study, in two parallel arms, comparing the pharyngeal clearance of Neisseria gonorrhoeae (NG) at 3 months with or without treatment with ceftriaxone. Experimental group: Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to Sexually Transmitted Infection or positive Polymerase chain reaction (PCR) at 3 months) Control group: Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal Polymerase chain reaction (PCR) again positive for NG during follow-up. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04269434 -
GonoScreen: Efficacy of Screening STIs in MSM
|
N/A | |
Completed |
NCT04094883 -
Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine
|
Phase 4 | |
Completed |
NCT01733069 -
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHERâ„¢ System
|
N/A | |
Completed |
NCT00978848 -
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
|
N/A | |
Recruiting |
NCT05286931 -
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
|
N/A | |
Completed |
NCT01329588 -
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
|
Phase 4 | |
Not yet recruiting |
NCT06369220 -
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
|
N/A | |
Completed |
NCT05216744 -
Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection
|
Phase 2 | |
Recruiting |
NCT05581160 -
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
|
N/A | |
Completed |
NCT02870101 -
Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT
|
N/A |